Table 1 Principal mixed cryoglobulinemia manifestations (clinical and biohumoral) diagnosed before treatment with rituximab and 3Â months after therapy
MC manifestations | Pre-treatment | 3Â months |
|---|---|---|
(%) | (%) | |
Clinical | Â | Â |
Purpura | 11 (78.56) | 1 (7.1) |
Arthralgias | 13 (92.96) | 4 (28.57) |
Neuropathic symptoms | 7 (50) | 3 (21.43) |
Renal involvment | 2 (14.28) | 1 (7.1) |
Skin ulcers | 1 (7.1) | 0 |
Sicca syndrome | 7 (50) | 5 (37.71) |
Biohumoral | Â | Â |
Cryocrit | 3.36 (1–12) | 1.46 (0–6) |
Rheumatoid factor | 12 (85.71) | 10 (71.43) |
Reduced C4 | 9 (64.3) | 5 (37.71) |